Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
June 28, 2004
- Lamivudine Prevents Liver Cancer in Hepatitis B Patients: JSH Meeting
June 28, 2004
- 70% of Subjects Express Affirmative View of Trials: JPMA Survey
June 28, 2004
- PRESS SEMINAR
June 28, 2004
- FJPWA Working to Ensure Proper Contracts with Medical Institutions
June 28, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 28, 2004
- MPC Expanding Product Line in the Field of Cerebrovascular Disease
June 28, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 28, 2004
- BUSINESS NEWS IN BRIEF
June 28, 2004
- WORLDNEWS IN BRIEF
June 28, 2004
- Annual Business Results
June 28, 2004
- FPMAJ Report Outlines Future Issues in Regard to NHI Drug Pricing
June 28, 2004
- NEW PRODUCTS
June 28, 2004
- Need for New Drug Pricing System Stressed: Korosho Conference
June 28, 2004
- ICH Topics Q8, Q9 Should Reach Step 2 in November
June 28, 2004
- REGULATORY NEWS IN BRIEF
June 28, 2004
- 40,000 May Have Died Due to Medical Malpractice in 2003: Symposium
June 28, 2004
- Korosho Holds Hearings on Progress of Action Plan
June 21, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 21, 2004
- White Paper on Manufacturing Urges International Competitiveness
June 21, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…